Structure Therapeutics surges after weight-loss drug succeeds mid-stage trial

Shares of Structure Therapeutics GPCR.O rise 82% to $63.04

GPCR's experimental drug aleniglipron at a dosage of 120 mg showed an 11.3% reduction in weight in a mid-stage study, a figure that was statistically significant compared to placebo at 36 weeks

The company plans to initiate a late-stage trial in mid-2026

Another study exploring higher doses of aleniglipron showed weight loss of up to 15.3% at 36 weeks

"It’s clear there is strong and broad interest in obesity assets, potentially providing additional momentum for the stock," J.P. Morgan analysts wrote in a note

Shares of other obesity drug makers and developers also slipped, with Viking Therapeutics VKTX.O down more than 4%, and dominant players Eli Lilly and U.S.-listed shares of Novo Nordisk falling more than 1% and 2.4%, respectively

Including the session's move, GPCR stock was up 95% YTD